Online Program

321692
Frequency and severity of medication related problems identified in community dwelling Medicare beneficiaries: Three year analyses of mobile clinic data


Monday, November 2, 2015 : 10:30 a.m. - 10:45 a.m.

Yvonne Mai, PharmD, Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Christine Cao, PharmD Candidate, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Tina Kwan, PharmD Candidate, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Patrick Lee, PharmD Candidate, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Joshua Tai, PharmD Candidate, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Cynthia S. Oseguera, PharmD, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA
Rajul A. Patel, PharmD, PhD, Department of Pharmacy Practice, University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences, Stockton, CA
background: Medication therapy management (MTM) is a process used to identify and prevent medication related problems (MRPs); thereby optimizing drug therapy. Many Medicare beneficiaries are more vulnerable to MRPs due to their complex medication regimens. We sought to examine the frequency and severity of MRPs through the provision of MTM services from 2012 to 2014. We also recorded prescriber acceptance of recommendations made.

methods: Thirty-nine Mobile Clinics targeting Medicare beneficiaries were conducted in Northern/Central California between Fall 2012-Fall 2014. Trained student pharmacists, supervised by licensed pharmacists, provided beneficiaries with comprehensive MTM services. Demographic, medical history, medication use data, and type and frequency of MRPs were recorded. With permission, severe MRPs and suggestions for resolution were communicated to the beneficiary’s prescriber(s). Prescriber follow-up helped determine acceptance of recommendations.

results: Of 2,099 beneficiaries assisted during the three year period, 1,217 (58.0%) had at least one MRP identified. Furthermore, 242 (11.5%) had one or more severe MRP, of which 186 (86.1%) were resolved by the prescriber. The number of MRPs was significantly positively correlated with the number of chronic disease states, prescriptions, and over-the-counter medications taken. Dual-eligible beneficiaries, those with less formal education, and non-English speakers were also significantly more likely to have a severe MRP.

conclusion: Many Medicare beneficiaries may have MRPs which can be easily addressed. Moreover, certain vulnerable beneficiary subgroups are at increased risk of suffering from a severe MRP. Improved communication between the pharmacist, beneficiary, and their prescriber can potentially have a significant positive impact on health outcomes.

Learning Areas:

Implementation of health education strategies, interventions and programs
Other professions or practice related to public health
Provision of health care to the public

Learning Objectives:
Identify the prevalence and types of medication related problems in the Medicare beneficiary population Discuss prescriber response to recommendations made for severe medication related problems identified Explain the impact medication therapy management (MTM) in improving medication use in the Medicare population

Keyword(s): Pharmacists, Outcomes Research

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been a primary and co-author of multiple research projects presented at national conferences including the American Public Health Association in the past. I am currently doing a fellowship in pharmacoeconomics and health outcomes and have worked extensively in medication therapy management and with Medicare beneficiaries, conducting research on health outcomes of the Medicare population.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.